

Minimal Residual Disease

NeoGenomics' Pharma Services offers Flow Cytometry Services including assays designed to detect and monitor Minimal Residual Disease (MRD) in hematologic cancers. Our newest platform (Becton Dickinson Fortessa X-20) and modular approach allow us to achieve the most clinically prognostic level of sensitivity using less sample than standard approaches because we can acquire up to 5 million events in a single tube. Our custom panels allow us to provide information on standard and exploratory markers to get the relevant information you want.



MRD Assays:



- Multiple Myeloma/Plasma Cells
- Chronic Lymphocytic Leukemia (CLL)
- Acute Lymphoblastic Leukemia (ALL)
- Custom assay design
- Assay Transfer

MRD flow assays vs standard flow assays:

	Standard Flow Assay	Neo MRD Flow Assays
Sensitivity	1%	Down to 0.001%
Parameters	≤ 8 Parameters	Up to 18 Parameters
Events Collected	10-20,000 Events	Up to 10 million events
Tubes	Multi-Tube Assay	Single or multi tube assay

Flow Cytometry Panels

Minimal Residual Disease Assessments	MRD	Parameters
	B-ALL MRD	CD45, CD38, CD34, CD19, CD10, CD22, CD20, CD58, CD9, CD71, CD13/CD33
	CLL MRD	CD5, CD3, CD81, CD79b, CD22, CD19, CD43, CD20
	MM MRD	KAPPA, LAMBDA, CD117, CD56, CD138, CD19, CD38, CD45, CD81, CD27, CD20



	% MRD of mononuclear	# MRD (Abnormal)	# Total B-cells	# Mononuclear cells
Tube 1	0.083%	189	40955	
Tube 2	0.076%	208	48966	
Tube 3			7092	39412

$$\%MRD = (Abnormal/B-cells+1)*(B-cells tube3/Mononuclear+1)*100$$